ABOUT

TO ACT. TO SAVE.

Who We Are

AGEM Bio is an early-stage clinical portfolio company, headquartered in Singapore, specializing in developing and building innovative cellular therapy assets.

Our Vision

To improve and save lives with precision-augmented mesenchymal stem cell biopharmacy.

Our Mission

To deliver effective interventions with impactful outcomes. Focusing on developing “living medicines” – safe and enhanced cell-gene products for the treatment of diseases.

Our Values

Courage

We pursue bold scientific ideas and tackle complex challenges with integrity, rigour, and conviction.

Resilience

We persist through uncertainty and setbacks, adapting and learning as we advance our long-term therapeutic goals.

Reliabiltiy

We hold ourselves accountable to the highest standards of quality, reproducibility, and trust in everything we deliver.

Esprit-de-corps

We foster a collaborative, respectful culture where shared purpose and collective effort drive success.

Innovation

We continuously push scientific boundaries through curiosity, creativity, and disciplined execution.

Our Story

Our technology was born at the Yong Loo Lin School of Medicine, National University of Singapore (NUS), where researchers pioneered a non-viral gene-engineering method that functionalise MSCs into therapeutic delivery vehicles. Capitalising on this, the team created their first proof-of-concept product (AGEM-102) to target treatment refractory solid tumours. Compassionate use in veterinary patients (2018 onwards) confirmed the approach could extend life and improve quality of life with minimal side-effects.
‍
In 2024, we spun out as AGEM Bio (Augmented Gene Modification) to translate this platform to human trials. Backed by SGInnovate and anchored at NUS’s E7 biotech incubator, we are now scaling GMP production and building partnerships that will bring precision cell therapies to patients across Asia and beyond.